drugset / Trial / NCT05917964

A Food Effect Study of LP-168 Tablets in Healthy Subjects

NCT05917964

Phase 1 Completed 22 enrolled Guangzhou Lupeng Pharmaceutical Company LTD.
RandomizedCrossoverOpen-labelTreatment

Summary

This is a randomized, two-period, two-sequence two-treatment crossover design food effect study to evaluate the pharmacokinetic profile of LP-168 tablets in healthy subjects after single oral administration under fasted and fed conditions

Timeline

Start
2023-06-21
Primary completion
2023-08-21
Completion
2023-08-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Rocbrutinib Small molecule 150 mg Oral

Indications